BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16951208)

  • 21. Valproic acid and all trans retinoic acid differentially induce megakaryopoiesis and platelet-like particle formation from the megakaryoblastic cell line MEG-01.
    Schweinfurth N; Hohmann S; Deuschle M; Lederbogen F; Schloss P
    Platelets; 2010; 21(8):648-57. PubMed ID: 20942599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid exerts differential effects on CXCR4 expression in leukemic cells.
    Gul H; Marquez-Curtis LA; Jahroudi N; Larratt LM; Janowska-Wieczorek A
    Leuk Res; 2010 Feb; 34(2):235-42. PubMed ID: 19539992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.
    Stapnes C; Ryningen A; Hatfield K; Øyan AM; Eide GE; Corbascio M; Kalland KH; Gjertsen BT; Bruserud Ø
    Int J Oncol; 2007 Dec; 31(6):1529-38. PubMed ID: 17982680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells.
    Awwad RT; Do K; Stevenson H; Fu SW; Lo-Coco F; Costello M; Campbell CL; Berg PE
    Ann Hematol; 2008 Mar; 87(3):195-203. PubMed ID: 18026954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
    Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
    Poggi A; Catellani S; Garuti A; Pierri I; Gobbi M; Zocchi MR
    Leukemia; 2009 Apr; 23(4):641-8. PubMed ID: 19151770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
    Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
    Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia.
    Shin HJ; Chung JS; Choi YJ; Cho GJ
    Am J Clin Oncol; 2009 Jun; 32(3):227-32. PubMed ID: 19433969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML.
    Khanim FL; Bradbury CA; Arrazi J; Hayden RE; Rye A; Basu S; MacWhannell A; Sawers A; Griffiths M; Cook M; Freeman S; Nightingale KP; Grimwade D; Falciani F; Turner BM; Bunce CM; Craddock C
    Br J Haematol; 2009 Feb; 144(3):332-41. PubMed ID: 19036090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute promyelocytic leukemia: recent advances in diagnosis and management.
    Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
    Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
    Ryningen A; Stapnes C; Lassalle P; Corbascio M; Gjertsen BT; Bruserud O
    Leuk Res; 2009 Jun; 33(6):779-87. PubMed ID: 19007987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.
    McDevitt MA; Condon M; Stamberg J; Karp JE; McDiarmid M
    Mutat Res; 2007 Apr; 629(1):24-31. PubMed ID: 17276720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New strategies for the treatment of acute myelogenous leukemia: differentiation induction--present use and future possibilities.
    Bruserud O; Gjertsen BT
    Stem Cells; 2000; 18(3):157-65. PubMed ID: 10840068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of neutrophilic differentiation of human promyelocytic leukemic cells by branched-chain carboxylic acid anticonvulsant drugs.
    Fischkoff SA; Walter E
    J Biol Response Mod; 1984; 3(2):132-7. PubMed ID: 6427413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
    Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
    Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia.
    Raza S; Ullah K; Ahmed P; Khan B
    J Coll Physicians Surg Pak; 2008 Sep; 18(9):546-50. PubMed ID: 18803891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
    Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M
    Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.